Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

SUTRO BIOPHARMA, INC. Director's Dealing 2021

Jan 16, 2021

34319_dirs_2021-01-15_b1e8a74e-f5e9-42ac-9756-ebcd5be0ab03.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SUTRO BIOPHARMA, INC. (STRO)
CIK: 0001382101
Period of Report: 2021-01-14

Reporting Person: Hallam Trevor (Chief Scientific Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-01-14 Common Stock M 19405 $4.36 Acquired 56117 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-01-14 Employee Stock Option (right to buy) $4.36 M 19405 Disposed 2022-09-19 Common Stock (19405) Direct

Footnotes

F1: The option is fully vested and exercisable.